Bonasia CG, Abdulahad WH, Rutgers A, Heeringa P, Bos NA (2021) B cell activation and escape of tolerance checkpoints: recent insights from studying autoreactive B cells. Cells 10(5):1190. https://doi.org/10.3390/cells10051190

Article  PubMed  PubMed Central  Google Scholar 

Zamvil SS, Hauser SL (2021) Antigen presentation by B cells in multiple sclerosis. N Engl J Med 384(4):378–381. https://doi.org/10.1056/nejmcibr2032177

Article  PubMed  PubMed Central  Google Scholar 

Shah K, Leandro M, Cragg M et al (2024) Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy? Clin Exp Immunol. https://doi.org/10.1093/cei/uxae031

Article  PubMed  PubMed Central  Google Scholar 

Prüss H (2021) Autoantibodies in neurological disease. Nat Rev Immunol 21(12):798–813. https://doi.org/10.1038/s41577-021-00543-w

Article  PubMed  PubMed Central  Google Scholar 

Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688. https://doi.org/10.1056/nejmoa0706383

Article  PubMed  Google Scholar 

Hawker K, O’Connor P, Freedman MS et al (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66(4):460–471. https://doi.org/10.1002/ana.21867

Article  PubMed  Google Scholar 

Montalban X, Hauser SL, Kappos L et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209–220. https://doi.org/10.1056/nejmoa1606468

Article  PubMed  Google Scholar 

Hauser SL, Bar-Or A, Cohen JA et al (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383(6):546–557. https://doi.org/10.1056/nejmoa1917246

Article  PubMed  Google Scholar 

Steinman L, Fox E, Hartung HP et al (2022) Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med 387(8):704–714. https://doi.org/10.1056/nejmoa2201904

Article  PubMed  Google Scholar 

Cree BAC, Bennett JL, Kim HJ et al (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394(10206):1352–1363. https://doi.org/10.1016/s0140-6736(19)31817-3

Article  PubMed  Google Scholar 

Yamamura T, Kleiter I, Fujihara K et al (2019) Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381(22):2114–2124. https://doi.org/10.1056/nejmoa1901747

Article  PubMed  Google Scholar 

Titulaer MJ, McCracken L, Gabilondo I et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165. https://doi.org/10.1016/s1474-4422(12)70310-1

Article  PubMed  PubMed Central  Google Scholar 

Thurlings RM, Teng O, Vos K et al (2010) Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 69(2):409. https://doi.org/10.1136/ard.2009.109041

Article  PubMed  Google Scholar 

Haghikia A, Schett G, Mougiakakos D (2024) B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. Lancet Neurol 23(6):615–624. https://doi.org/10.1016/s1474-4422(24)00140-6

Article  PubMed  Google Scholar 

Zografou C, Vakrakou AG, Stathopoulos P (2021) Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders. Front Immunol 12:686466. https://doi.org/10.3389/fimmu.2021.686466

Article  PubMed  PubMed Central  Google Scholar 

Kouhi A, Pachipulusu V, Kapenstein T, Hu P, Epstein AL, Khawli LA (2021) Brain disposition of antibody-based therapeutics: dogma, approaches and perspectives. Int J Mol Sci 22(12):6442. https://doi.org/10.3390/ijms22126442

Article  PubMed  PubMed Central  Google Scholar 

Gong Q, Ou Q, Ye S et al (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174(2):817–826. https://doi.org/10.4049/jimmunol.174.2.817

Article  PubMed  Google Scholar 

Snowden JA (2016) Rebooting autoimmunity with autologous HSCT. Blood 127(1):8–10. https://doi.org/10.1182/blood-2015-11-678607

Article  PubMed  Google Scholar 

Bayas A, Berthele A, Blank N et al (2023) Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline. Ther Adv Neurol Disord 16:17562864231180730. https://doi.org/10.1177/17562864231180730

Article  PubMed  PubMed Central  Google Scholar 

Burt RK, Han X, Quigley K, Helenowski IB, Balabanov R (2022) Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis. J Neurol 269(5):2513–2526. https://doi.org/10.1007/s00415-021-10820-2

Article  PubMed  Google Scholar 

Lambertini M, Mastro LD, Pescio MC et al (2016) Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 14(1):1. https://doi.org/10.1186/s12916-015-0545-7

Article  PubMed  PubMed Central  Google Scholar 

Muraro PA, Pasquini M, Atkins HL et al (2017) Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol 74(4):459. https://doi.org/10.1001/jamaneurol.2016.5867

Article  PubMed  PubMed Central  Google Scholar 

Danylesko I, Shimoni A (2018) Second malignancies after hematopoietic stem cell transplantation. Curr Treat Options Oncol 19(2):9. https://doi.org/10.1007/s11864-018-0528-y

Article  PubMed  Google Scholar 

Mougiakakos D, Krönke G, Völkl S et al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385(6):567–569. https://doi.org/10.1056/nejmc2107725

Article  PubMed  Google Scholar 

Bergmann C, Müller F, Distler JHW et al (2023) Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 82(8):1117–1120. https://doi.org/10.1136/ard-2023-223952

Article  PubMed  Google Scholar 

Lee J, Lundgren DK, Mao X et al (2020) Antigen-specific B-cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Investig 130(12):6317–6324. https://doi.org/10.1172/jci138416

Article  PubMed  PubMed Central  Google Scholar 

Müller F, Boeltz S, Knitza J et al (2023) CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401(10379):815–818. https://doi.org/10.1016/s0140-6736(23)00023-5

Article  PubMed  Google Scholar 

Pecher AC, Hensen L, Klein R et al (2023) CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329(24):2154–2162. https://doi.org/10.1001/jama.2023.8753

Article  PubMed  PubMed Central  Google Scholar 

Müller F, Taubmann J, Bucci L et al (2024) CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up. N Engl J Med 390(8):687–700. https://doi.org/10.1056/nejmoa2308917

Article  PubMed  Google Scholar 

Granit V, Benatar M, Kurtoglu M et al (2023) Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol 22(7):578–590. https://doi.org/10.1016/s1474-4422(23)00194-1

Article  PubMed  PubMed Central